Kezar Life Sciences, Inc. (KZR): Price and Financial Metrics
KZR Price/Volume Stats
| Current price | $2.86 | 52-week high | $11.02 |
| Prev. close | $2.78 | 52-week low | $2.25 |
| Day low | $2.73 | Volume | 431,100 |
| Day high | $2.88 | Avg. volume | 878,113 |
| 50-day MA | $2.72 | Dividend yield | N/A |
| 200-day MA | $6.20 | Market Cap | 207.08M |
KZR Stock Price Chart Interactive Chart >
Kezar Life Sciences, Inc. (KZR) Company Bio
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Latest KZR News From Around the Web
Below are the latest news stories about KEZAR LIFE SCIENCES INC that investors may wish to consider to help them evaluate KZR as an investment opportunity.
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., April 05, 2023--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted six employees nonqualified stock options to purchase 232,000 shares of its common stock with an exercise price of $3.05 per share, which is equal to the closing price of Kezar’s common s |
Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business UpdateSOUTH SAN FRANCISCO, Calif., March 14, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update. |
Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023SOUTH SAN FRANCISCO, Calif., March 13, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull forward its virtual Research and Development (R&D) Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT. |
Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023SOUTH SAN FRANCISCO, Calif., March 06, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a virtual Research and Development (R&D) Day on Wednesday, March 22, 2023 at 4:30 pm ET/1:30 pm PT. |
Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care ConferenceSOUTH SAN FRANCISCO, Calif., March 01, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen Roth Henig, M.D., Chief Medical Officer, will participate on the Autoimmune/Complement/Inflammation panel discussion at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 10:30 am ET in Boston, MA. |
KZR Price Returns
| 1-mo | 10.00% |
| 3-mo | -49.38% |
| 6-mo | -59.55% |
| 1-year | -43.25% |
| 3-year | -36.02% |
| 5-year | N/A |
| YTD | -59.38% |
| 2022 | -57.89% |
| 2021 | 220.31% |
| 2020 | 30.17% |
| 2019 | -83.01% |
| 2018 | N/A |
Loading social stream, please wait...